Emmaus Life Sciences Inc (EMMA)
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company listed on OTC Markets under the ticker EMMA. The company develops, markets, and sells therapies focused primarily on rare and orphan diseases in the United States and abroad. Its lead product is Endari, an oral L-glutamine powder approved for reducing acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Emmaus also has a development pipeline that includes ELS004, a pharmaceutical-grade L-glutamine candidate in Phase 1 testing for diverticulosis, along with preclinical programs such as ELS005 for blood cancers, ELS003 as a research tool for measuring cell sheet transmittance, and ELS002 for cartilage-related applications in the knee and osteoarthritis. The company also has a licensing agreement with Kainos Medicine covering an IRAK4 inhibitor for certain cancers. Emmaus Life Sciences was founded in 2000 and is headquartered in Torrance, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-EMMA
|
$0.011
|
15.0% Upside
|
Fair
|
—
|
—
|
—
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 17, 2026
|
-0.1x
|
0.0x
|
0.1x
|
823.308 K
|
20.022 M
|
97.9%
|
65.6%
|
-23.9
|
—
|
7.5%
|
